Discovery Life Sciences partnered with Mindpeak to apply AI-assisted tissue biomarker analysis across clinical trial workflows and translational research. The collaboration aims to reduce variability in slide interpretation between pathologists by combining Mindpeak’s AI pathology tools with Discovery’s flow cytometry and histopathology services. The partnership is positioned around better biomarker quantification and improved reproducibility, which can tighten the evidentiary link between molecular markers and clinical outcomes in trials. Discovery previously worked with PathAI on an AI tissue analysis panel, and this new tie extends the company’s tooling for biomarker development. Next milestones include defined use cases and trial settings where the joint workflow can demonstrate reductions in interpretation discrepancies and measurable improvements in biomarker consistency.